Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
13.55
-0.81 (-5.61%)
Apr 10, 2025, 1:39 PM EDT - Market open
Travere Therapeutics Employees
Travere Therapeutics had 385 employees as of December 31, 2024. The number of employees increased by 5 or 1.32% compared to the previous year.
Employees
385
Change (1Y)
5
Growth (1Y)
1.32%
Revenue / Employee
$605,649
Profits / Employee
-$835,182
Market Cap
1.20B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TVTX News
- 9 days ago - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - Business Wire
- 24 days ago - Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - GlobeNewsWire
- 4 weeks ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS - GlobeNewsWire